Park 2016.
Study characteristics | ||
Methods | Parallel | |
Participants | 103: 38 male (age 53.2, 55.6, 51.4, 50.8) Moderate/severe (based on ICS dose (medium/high), exacerbation history, and ACQ ≥ 1.5 on at least 2 occasions) participants also had to demonstrate post‐bronchodilator FEV1 reversibility ≥ 12% and ≥ 200 mL, or a positive response to methacholine challenge (PC20 ≤ 8 mg/mL)
|
|
Interventions | SC doses given at weeks 1, 4, 8, 16, 24, 32, 40. Benralizumab 2 mg, 20 mg or 100 mg SC | |
Outcomes | Primary outcomes
Secondary outcomes
Exploratory endpoints included blood eosinophil counts. |
|
Notes | 32 sites in South Korea and Japan | |
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Low risk | Eosinophilic participants were randomised using a central, interactive web‐response system |
Allocation concealment (selection bias) | Unclear risk | Not stated, no clarification available from study authors |
Blinding of participants and personnel (performance bias) All outcomes | Low risk | The study medication was administered … in a blinded fashion |
Blinding of outcome assessment (detection bias) All outcomes | Unclear risk | Not stated, no clarification available from study authors |
Incomplete outcome data (attrition bias) All outcomes | Low risk | Attrition rates relatively high but even across groups (19.2% for placebo vs 16.0%‐23.1% for treatment groups) |
Selective reporting (reporting bias) | Low risk | All outcomes reported |